Replies to post #59300 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Whereas, unlike DCVax-L, with DCVax-Direct, because the tumor gets a crack at trying to suppress DCVax-Direct cells when they are injected into a live tumor, DCVax-Direct uses specific types of cytokine secretion that can:

1. Override at least a certain amount of checkpoint molecule suppression (checkpoint molecules occur in many types of immune cells),
2. Increase DC migration,
3. Increase chemoattraction for other immune cell recruitment, and
4. Increase death by apoptosis -- which also necessarily increases DC antigen uptake, further immune response and removal of dead tumor tissue.
5. Overall makes the tumor microenvironment more susceptible for the ensuing T-cell attack.

Just as speculated in my last post about DCVax-L, CIs would apparently be helpful, particularly in low immunogenic but aggressive cancers, but perhaps, just guessing, the amount of CIs needed would be reduced by DCVax-Direct's MOA, and perhaps because the CIs could be injected intratumorally as well. JMO. Just trying to understand this.

[Doc logic]

flipper44,

I believe you are on the right track and there are certain DCs (if I recall correctly) that can survive in a hypoxic environment longer than others and or can also secrete higher levels of cytokines to generate a stronger immune response from infiltrating lymphocytes and ancilaries while controlling immunosuppression better.